Wockhardt gets favourable recommendation from CDSCO for antibiotic for CABP

Wockhardt's new antibiotic, Miqnaf, has received a favourable recommendation from the Central Drugs Standard Control Organisation for treating community-acquired bacterial pneumonia in adults. The drug offers a convenient, once-a-day, three-day treatment. This could lead to final approval by the DCGI, benefiting patients with multi-drug resistant infections. Wockhardt shares rose by 5 percent.